Biomarkers /
SMARCA2
Overview
SMARCA2 is altered in 3.17% of all cancers with conventional glioblastoma multiforme, glioblastoma, colorectal adenocarcinoma, diffuse intrinsic pontine glioma, and high-grade glioma, NOS having the greatest prevalence of alterations [3].
The most common alterations in SMARCA2 are SMARCA2 Q229P (0.26%), SMARCA2 Q234P (0.26%), SMARCA2 E501G (0.13%), SMARCA2 Q228_Q229delinsP (0.18%), and SMARCA2 Q238del (0.08%) [3].
Clinical Trials
Significance of SMARCA2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.